CHIEN-HSIEH CHIANGKUO-CHIN HUANG2021-01-142021-01-1420150270-9139https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928210047&doi=10.1002%2fhep.27427&partnerID=40&md5=2aa1932f524dc3d60f12065fe6fad917https://scholars.lib.ntu.edu.tw/handle/123456789/540673[SDGs]SDG3antidiabetic agent; cancer diagnosis; cancer mortality; cancer risk; cardiovascular mortality; cause of death; death certificate; diabetes mellitus; disease duration; dyslipidemia; follow up; hepatitis B; human; Letter; liver cell carcinoma; priority journal; questionnaire; diabetes mellitus; Dyslipidemias; female; liver cell carcinoma; liver tumor; male; mortality; Carcinoma, Hepatocellular; Diabetes Complications; Dyslipidemias; Female; Humans; Liver Neoplasms; Maleletter10.1002/hep.27427252054372-s2.0-84928210047